• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Recent Advances in the Study of Methyl 3,5-dibromo-2,4-dihydroxybenzoate (CAS: 885279-78-7) and Its Applications in Chemical Biology and Medicine

Methyl 3,5-dibromo-2,4-dihydroxybenzoate (CAS: 885279-78-7) is a brominated aromatic compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has been the subject of numerous studies aimed at exploring its biological activities, synthetic pathways, and therapeutic potential. The presence of bromine atoms and hydroxyl groups in its structure makes it a promising candidate for various biochemical interactions and drug development endeavors.

Recent research has focused on the synthesis and optimization of Methyl 3,5-dibromo-2,4-dihydroxybenzoate, with particular emphasis on improving yield and purity. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that utilizes catalytic bromination and esterification under mild conditions, achieving a high yield of 85%. This advancement addresses previous challenges associated with the compound's synthesis, such as low efficiency and the formation of unwanted byproducts. The study also highlighted the compound's stability under physiological conditions, which is a critical factor for its potential use in drug formulations.

In the realm of biological activity, Methyl 3,5-dibromo-2,4-dihydroxybenzoate has demonstrated notable antimicrobial properties. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that the compound exhibited strong inhibitory effects against a range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 2 μg/mL. The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, a mechanism that differs from conventional antibiotics. These findings suggest its potential as a lead compound for developing new antimicrobial agents, particularly in the face of rising antibiotic resistance.

Beyond its antimicrobial effects, Methyl 3,5-dibromo-2,4-dihydroxybenzoate has also been investigated for its anticancer properties. A recent study in the European Journal of Medicinal Chemistry (2023) explored its effects on various cancer cell lines, including breast and lung cancer. The results indicated that the compound induced apoptosis in cancer cells through the activation of the intrinsic mitochondrial pathway. Furthermore, it showed selective cytotoxicity, sparing normal cells at concentrations effective against cancerous ones. This selectivity is a promising attribute for anticancer drug development, as it could minimize adverse side effects commonly associated with chemotherapy.

The compound's potential extends to neurodegenerative diseases as well. A 2023 study in ACS Chemical Neuroscience revealed that Methyl 3,5-dibromo-2,4-dihydroxybenzoate could modulate oxidative stress and reduce neuroinflammation in vitro. The researchers found that it acted as a scavenger of reactive oxygen species (ROS) and inhibited the production of pro-inflammatory cytokines in microglial cells. These properties position the compound as a candidate for further investigation in the treatment of conditions like Alzheimer's and Parkinson's diseases, where oxidative stress and inflammation play critical roles.

Despite these promising findings, challenges remain in the development and application of Methyl 3,5-dibromo-2,4-dihydroxybenzoate. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive preclinical studies. Future research directions may include structural modifications to enhance its pharmacokinetic properties and in vivo efficacy. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to translate these laboratory findings into clinical applications.

In conclusion, Methyl 3,5-dibromo-2,4-dihydroxybenzoate (CAS: 885279-78-7) represents a versatile and promising compound in chemical biology and medicine. Its diverse biological activities, coupled with recent advancements in its synthesis, underscore its potential as a foundation for developing new therapeutic agents. Continued research and innovation will be key to unlocking its full potential and addressing the unmet medical needs in antimicrobial, anticancer, and neurodegenerative therapies.

• 4068-76-2(methyl 5-bromo-2-hydroxybenzoate)
• 706820-79-3(Methyl 3-bromo-5-formyl-4-hydroxybenzoate)
• 39503-51-0(Methyl 5-bromo-2,4-dimethoxybenzoate)
• 15790-59-7(Methyl 3,5-dibromo-2-methoxybenzenecarboxylate)
• 28165-45-9(Methyl 3-bromo-2-hydroxybenzoate)
• 21702-79-4(Methyl 3,5-dibromo-2-hydroxybenzoate)
• 65977-12-0(Methyl 3-bromo-2,6-dimethoxybenzoate)
• 39503-52-1(Methyl 5-bromo-2-hydroxy-4-methoxybenzoate)
• 98437-43-5(5-Bromo-2,4-dihydroxybenzoic Acid Methyl Ester)
• 185050-77-5(Methyl 5-bromo-4-hydroxy-2-methoxybenzoate)